Board of Directors
Srinivasan H R
Chairman & CEO
Navitas Life Sciences
Srinivasan H.R., fondly known as Sri, is the Chief Executive Officer of Navitas Life Sciences. He brings rich experience in Life Sciences, Supply Chain Management and General Management. Sri has run efficient global organizations, as well as led multiple successful mergers & acquisitions. His decades of experience have been pivotal in the establishment of Navitas Life Sciences.
Sri started his career as a Civil Servant in the Government of India. Post that, he successfully held several leadership roles including Executive Director of the Shriram Group, Managing Director of Sembcorp Logistics, Singapore, Managing Director of Temasek Capital, Singapore among others. He has served both on the State and Regional Councils of the Confederation of Indian Industry. He has also served as the Past President of TiE (The Indus Entrepreneurs), Chennai Chapter. In 2008, Sri was conferred with the CII Connect – “Entrepreneur of the Year” and the CII Tamil Nadu “Emerging Entrepreneur” award in 2010. He is a member of the YPO (Young Presidents Organisation).
Srinivasan H RChairman & CEO
Navitas Life Sciences
Camilo E. Horvilleur
Camilo is a Managing Director in the U.S. LBO fund and is based in H.I.G.'s Miami office, where he focuses on investment sourcing, transaction negotiation, and portfolio company value creation strategies. Since joining H.I.G. Capital’s U.S. LBO group in 2006, he has helped lead private equity investments in a number of industries including life sciences, healthcare services and business services. Camilo has served on the board of directors of several H.I.G. companies including Navitas Life Sciences, Medusind, Health Network One, US Medical Supply, Capstone Logistics, Koozie Group, Safe-Guard Products, PMSI and Align Networks.
Prior to joining H.I.G., Mr. Horvilleur was with Morgan Stanley in New York, where he focused on communications services and emerging markets. Mr. Horvilleur earned his B.B.A. in Finance from Texas A&M University, summa cum laude, and M.B.A. from Harvard Business School.
Camilo E. HorvilleurBoard Member,
Scott is a Principal in H.I.G. Capital’s Miami office. He is responsible for all aspects of the investment process including sourcing, transaction structuring, financing, and execution of post-closing value creation strategies. Since joining H.I.G. in 2009, Scott has helped lead private equity investments in a number of industries including healthcare, TMT, chemicals, and business services. Scott serves on the board of directors for a number of H.I.G.’s investments including BioVectra, Valtris Specialty Chemicals, Health Network One, and Navitas Life Sciences.
Prior to his current role at H.I.G., Scott was also a member of the management team at a H.I.G. portfolio company, PMSI, a pharmacy benefit manager eventually acquired by Optum, an investor at Staple Street Capital, and a member of the Technology, Media and Telecom group at Bank of America Merrill Lynch. Scott received his undergraduate degree from Yale University.
Scott ZhuBoard Member,
Managing Director & Co-Head of Biohealth ,
Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. He joined H.I.G. BioHealth Partners as a Managing Director in January 2016. He currently serves on the board of directors for Arvelle Therapeutics, Clarus Therapeutics, Leiters Pharmacy, Neurana Pharmaceuticals, Taconic Biosciences, BioVectra, Orbus Therapeutics, and On Target Laboratories.
Prior to H.I.G., Alex spent 13 years making similar investments at Thomas, McNerney & Partners.
Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Alex became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).
Alex is the co-chair of the Industry Advisory Board of the Children’s Tumor Foundation, is on the Advisory Board for Brown University’s Medical School and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America.
He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.
Alex ZissonBoard Member,
Managing Director &
Co-Head of Biohealth
Ex-Chief Operating Officer,
Navitas Data Sciences
Paul Gilbert is Chief Operating Officer of Navitas Data Sciences business unit of Navitas Life Sciences. Paul leads the Global Data Sciences Functional Service Provider business. Previous to the Navitas acquisition, Paul was Cofounder and President of DataCeutics for over 25 years. Paul has been leading highly experienced statistical programmers, biostatisticians and data managers at DataCeutics, a Functional Service Provider to the pharmaceutical and biotech industry.
Paul is a recognized industry expert with more than forty years of experience in the pharmaceutical, biotech and CRO industries. His expertise encompasses clinical research business processes, industry standards and regulations, statistical programming process and delivery, CDISC standards, SAS programming, clinical reporting applications and clinical systems development. He has a strong command of every aspect of Information Technology utilized within Clinical Research.
Paul has served as the primary liaison with customers and vendors; managed subcontractors and contracts; and defined project and performance goals. He ensures that all contracted services and expectations of projects are carried out by the project team in accordance with the customer's expectations.
Paul GilbertBoard Member,
Ex-Chief Operating Officer, Navitas Data Sciences
Senior Vice President,
Tran is a Senior Vice President based in H.I.G. Capital's Miami office. He is responsible for various aspects of the investment process, including transaction structuring, financing, and execution of portfolio company value creation strategies. Tran has private equity experience across a number of industries, including healthcare, business services, TMT, and industrials.
Prior to joining H.I.G. in 2015, he was a member of the Industrials group at Wells Fargo Securities. Tran received his undergraduate degree from Duke University.
Tran KingBoard Member,
Senior Vice President
Marty BoomGlobal Head, Regulatory & PV
Bala LatupalliExecutive Vice President, Technology and Shared Services
Kalyan GopalakrishnanExecutive Vice President, Navitas Data Sciences
Louise JebsonHead of Consulting & NETS
Govind SrinivasanSenior VP – Business Partner, Regulatory & Safety Technology
Dr Ayaaz Hussain KhanGlobal Head, Generics
Sowmya KaurExecutive Vice President – Navitas Clinical Research
Dr Yun LuVP & Chief Science and Innovation Officer,
Navitas Clinical Research
Kathy GreerExecutive Vice President Professional Services, Navitas Data Sciences
Srinivasan H RChief Executive Officer
Lalit MahapatraChief Financial Officer
Shobana NSChief of Staff to CEO &
Chief Risk Officer